* If you want to update the article please login/register
Metastatic breast cancer to the bladder is extremely unusual, with only 66 cases reported in the literature to date. Metastatic breast cancer can first appear as a result of a planned retroperitoneal spread. We discuss a case in which a 77-year-old Caucasian female was discovered to have acute urinary blockage from metastatic breast cancer to the bladder. 0% of tumor cells were positive for PD-L1 gene expression, with PD-L1 expression found in 0 percent of tumor cells. Despite bilateral ureteral stent placement and, subsequently, percutaneous nephrostomy tube placement, the patient suffered renal impairment, requiring percutaneous nephrostomy tube placement.
Source link: https://doi.org/10.46570/utjms.vol7-2020-332
Background: Patients with HER2-positive metastatic breast cancer receive first-line treatment with anti-HER2 antibodies and have already received anti-HER2 therapy as adjuvant or neoadjuvant therapy in the local setting of their disease presentation. We wanted to see if prior exposure influenced the clinical outcomes of patients treated with anti-HER2-infused anti-Her2 medications compared to patients who were new to anti-HER2 agents. Methods: We conducted a retrospective observational study of HER2-positive MBC patients who were treated with trastuzumab and peruzumab from 2014 to 2018. TTP was significantly higher among patients with no prior exposure to anti-HER2 therapy in comparison to patients with previous exposure to anti-Her2 therapy, and we saw a trend toward improved OS. Conclusion: According to our review, prior exposure to anti-Her2 agents may have an effect on the clinical outcomes of first-line treatment of metastatic HER2 patients.
Source link: https://doi.org/10.1159/000516936
Abstract triple-negative breast cancer is a highly metastatic breast cancer subtype, and TNBC has limited therapeutic options with chemotherapy being the most common option for systemic therapy, with triple-negative breast cancer being a highly metastatic breast cancer subtype. Long-hairpin RNA -mediated LIM domain kinase 2 is overexpressed in TNBC, and short-hairpin RNA-mediated LIMK2 knockdown or its pharmacological inhibition blocks metastatic properties of TNBC cells. We found SRSF protein kinase 1, which encodes for a serine/arginine protein kinase specific to the SR family's splicing factors. Moreover, genetic inhibition of SRPK1 by shRNAs or its pharmacological inhibition impaired TNBC cells' metastatic properties. In sum, these findings identified LIMK2 as a source of distal TNBC metastasis and a potential threat to inhibiting TNBC metastatic progression.
Source link: https://doi.org/10.1038/s41389-020-00263-1
In women with non-metastatic breast cancer, this descriptive systematic review explored the relationship between personality and QoL. personality had a small to moderate effect on QoL, with correlation coefficients ranging from 0. 10 to 0. 77, and the explained variance ranged from 4 to 43 percent. The relationship was dependent on the personality trait and QoL domain that was measured, and it was most apparent for the personality traits of "optimism" and "trait anxiety" on psychosocial QoL domains. Conclusions The results show that personality plays a role in QoL in women with non-metastatic breast cancer, and therefore provides evidence that personality traits are significant predictors of QoL. QoL's low or deterioration of QoL provides physicians and patients with an interpretation of decreased or deterioration of QoL, which may lead to physicians' health outcomes and, in turn, QoL using psycho-oncological assistance or therapy.
Source link: https://doi.org/10.1186/s12885-022-09408-4
In comparison with other alternative therapies in the first line therapy of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative MBC in Iran, MethodsCUA was performed using a partitioned survival model from the Iranian healthcare system perspective. According to Letrozole mono-therapy, the Palbociclib+Letrozole and Ribociclib+Letrozole's incremental cost-effectiveness ratio improved for a long time compared to Letrozole monotherapy was expected between $ 137,302 and $ 120,478 per year adjusted life year, indicating a considerable distance from the target threshold. Conclusions albociclib+letrozole and Ribociclib+letrozole both showed significant results in the comparison to Letrozole based on the PFS, but not cost-effective measures in the first line treatment of MBC were not cost-effective, according to PSA, but not in the first line treatment of MBC.
Source link: https://doi.org/10.21203/rs.3.rs-1148837/v1
Abstract Abstract: MicroRNAs and chemotherapeutic agents' incorporation into tumor cells is an effective therapy for synergetic breast cancer therapy due to their compatibility. Both transcription and protein levels, as well as cell proliferation, stunted tumor cell proliferation, and effectively promoted cell apoptosis and cytotoxicity in mice. In vitro, the co-delivery nanocarriers, suppressed the expression of anti-apoptosis gene Bcl-2, stunted tumor cell proliferation, stifled tumor cell proliferation, which inhibited tumor cell proliferation, as well as cytotoxicity. The current nanocarrier co-loading with DTX and miRNA-34a is a new nanoplatform for the treatment of metastatic breast cancer, and it comes as a new nanoplatform for the delivery of insoluble drugs and gene/protein peptides.
Source link: https://doi.org/10.1038/srep46186
This research sought to determine how disseminating ILC cells influence the balance between quiescence and cell cycle re-entry. We chose Inhibitor of DNA binding 2 (a mediator of cell cycle progression) from the genes that are upregulated in anchorage-dependent ILC cells, which is a mediator of cell cycle progression. In the opposite case, stable inducible revival of E-cadherin expression in the ILC cell line SUM44PE reduces Id2 expression and anoikis resistance. And, we find that Id2 is indeed rich in ILC when compared to other breast cancers, as well as determining cytosolic Id2 protein expression in primary ILC samples. E-cadherin and Id2 are promising tools to stratify low and middle-grade invasive breast cancers for the use of clinical cell cycle intervention drugs, as such.
Source link: https://doi.org/10.1038/s41388-022-02314-w
Abstract Background: Breast cancer has been a leading cancer diagnosis in women for a long time, and approximately 90 percent of cancer-related deaths are caused by metastasis. SQSTM's effects in tumor cells are regarded as a risk factor, in general, although protective factors are assigned to the other five genes in immune cells. Conclusions Our findings will lead to a more accurate estimation of breast cancer's metastatic status and will improve breast cancer metastasis-related biomarkers mining.
Source link: https://doi.org/10.1186/s12967-022-03369-9
Abstract The most life-threatening feature of breast cancer is the occurrence of metastatic disease. The tumor draining lymph nodes are often the first sites of breast cancer metastasis. Marrow xenografts and tumor xenografts grown from circulating tumor cell lines in mice with metastatic MDA-MB-231 and SUM159 tumor xenografts and tumor xenografts increased collagen I density in mice with no tumor tissue and mice with non-metastatic T-47D and MCF-7 tumor xenografts. Clinically, collagen synthesis in the lymph nodes may be a useful indicator of identifying lymph nodes that have been invaded by breast cancer cells.
Source link: https://doi.org/10.1038/srep10002
Metastasis has been attributed to the presence of circulating tumour cells and disseminated tumour cells in breast cancer patients' blood and bone marrow, respectively, but the expression of EMT markers in these cells has not been reported so far. Overall Results Among early breast cancer survivors, vimentin-and-Thower-expressing CK+CTCs were found in 77% and 73% of the patients, respectively, and in 100% of patients with metastatic breast cancer for both types of cancers. Patients with metastatic patients had 98% and 100 percent, respectively, and in an adjuvant chemotherapy setting, the corresponding numbers were 56% and 40. 6%. These cells are found in patients with metastatic disease in comparison to early stage breast cancer, supporting the belief that EMT is involved in CTC's metastatic potential.
Source link: https://doi.org/10.1186/bcr2896
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions